Lee H. Kalowski
Net Worth

Last updated:

What is Lee H. Kalowski net worth?

The estimated net worth of Mr. Lee H. Kalowski is at least $4,889,931 as of 3 Apr 2023. He owns shares worth $217,012 as insider, has earned $892,269 from insider trading and has received compensation worth at least $3,780,650 in Bicycle Therapeutics plc.

What is the salary of Lee H. Kalowski?

Mr. Lee H. Kalowski salary is $756,130 per year as Pres & Chief Financial Officer in Bicycle Therapeutics plc.

How old is Lee H. Kalowski?

Mr. Lee H. Kalowski is 44 years old, born in 1981.

What stocks does Lee H. Kalowski currently own?

As insider, Mr. Lee H. Kalowski owns shares in one company:

Company Title Shares Price per share Total value
Bicycle Therapeutics plc (BCYC) Pres & Chief Financial Officer 30,309 $7.16 $217,012

What does Bicycle Therapeutics plc do?

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

BCYC logo
BCYC
Bicycle Therapeutics plc
$7.16

Lee H. Kalowski insider trading

Bicycle Therapeutics plc

Mr. Lee H. Kalowski has made 13 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 376 units of BCYC stock worth $7,937 on 3 Apr 2023.

The largest trade he's ever made was exercising 17,189 units of BCYC stock on 23 Nov 2020. As of 3 Apr 2023 he still owns at least 30,309 units of BCYC stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Ordinary Shares 376 $21.11 $7,937
Sale
Ordinary Shares 1,815 $29.06 $52,744
Option
Employee Stock Option (right to buy) 10,000 $9.82 $98,200
Sale
Ordinary Shares 10,000 $9.82 $98,200
Option
Ordinary Shares 10,000 $9.82 $98,200
Option
Ordinary Shares 7,950 $35.15 $279,443
Option
Stock Option (Right to Buy) 7,950 $35.15 $279,443
Sale
Ordinary Shares 7,950 $35.15 $279,443
Sale
Ordinary Shares 550 $8.76 $4,818
Option
Stock Option (Right to Buy) 550 $8.76 $4,818
Option
Ordinary Shares 550 $8.76 $4,818
Sale
Ordinary Shares 7,500 $1.6 $12,000
Option
Ordinary Shares 7,500 $1.6 $12,000
Option
Stock Option (Right to Buy) 7,500 $1.6 $12,000
Sale
Ordinary Shares 12,500 $32.06 $400,750
Option
Stock Option (Right to Buy) 12,500 $1.63 $20,375
Option
Ordinary Shares 12,500 $1.63 $20,375
Option
Stock Option (Right to Buy) 15,000 $1.59 $23,850
Sale
Ordinary Shares 15,000 $1.59 $23,850
Option
Ordinary Shares 15,000 N/A N/A
Option
Stock Option (Right to Buy) 10,000 $1.6 $16,000
Option
Ordinary Shares 10,000 $1.6 $16,000
Sale
Ordinary Shares 10,000 N/A N/A
Option
Stock Option (Right to Buy) 7,500 $1.56 $11,700
Sale
Ordinary Shares 7,500 $1.56 $11,700
Option
Ordinary Shares 7,500 N/A N/A
Option
Stock Option (Right to Buy) 530 N/A N/A
Option
Ordinary Shares 530 N/A N/A
Sale
Ordinary Shares 530 $1.56 $827
Sale
Ordinary Shares 9,781 N/A N/A
Option
Stock Option (Right to Buy) 9,781 N/A N/A
Option
Ordinary Shares 9,781 $20.07 $196,305
Option
Ordinary Shares 17,189 $1.56 $26,815
Sale
Ordinary Shares 17,189 N/A N/A
Option
Stock Option (Right to Buy) 17,189 $1.56 $26,815

Bicycle Therapeutics key executives

Bicycle Therapeutics plc executives and other stock owners filed with the SEC:

  • Dr. Dominic Smethurst M.A., M.D. (51) Chief Medical Officer
  • Dr. Kevin Lee M.B.A., Ph.D. (56) Chief Executive Officer & Executive Director
  • Dr. Michael Skynner Ph.D., B.sc. Ph.d. (55) Chief Operating Officer
  • Dr. Nigel Crockett Ph.D. (60) Chief Bus. Officer
  • Mr. Lee H. Kalowski (44) Pres & Chief Financial Officer
  • Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE (74) Co-Founder, Non-Executive Director & Member of Scientific Advisory Board